Xu‐Chao Zhang

9.0k citations

162 papers · 5.2k indexed · 3 hit papers · h-index 37

Oncology top 0.5%
- Lung Cancer Research Studies 36
- Colorectal Cancer Treatments and Studies 30
- Cancer Immunotherapy and Biomarkers 21
Pulmonary and Respiratory Medicine top 0.5%
- Lung Cancer Treatments and Mutations 121
- Lung Cancer Diagnosis and Treatment 28
Cancer Research top 1%
- Cancer Genomics and Diagnostics 33
Molecular Biology top 5%
- PI3K/AKT/mTOR signaling in cancer 12
- Cancer therapeutics and mechanisms 9
Pathology and Forensic Medicine top 5%

Co-authors: Yi‐Long Wu Jin‐Ji Yang Qing Zhou Jian Su Wen‐Zhao Zhong Hong‐Hong Yan Zhi Xie Hai‐Yan Tu
Cited by: Oncology Pulmonary and Respiratory Medicine Cancer Research
Journals: Nature Communications (1 paper)Journal of Clinical Oncology (21 papers)SHILAP Revista de lepidopterología (3 papers)
Partner nations: China United States Hong Kong

In The Last Decade

Xu‐Chao Zhang

158 papers receiving 5.1k citations

Hit Papers

align trajectories log scale

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

2024 Research in International Business and Finance
2023 Cell Reports Medicine
2016 Clinical Cancer Research

Peers

Countries citing papers authored by Xu‐Chao Zhang

Since Specialization

Citations

This map shows the geographic impact of Xu‐Chao Zhang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xu‐Chao Zhang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xu‐Chao Zhang more than expected).

Fields of papers citing papers by Xu‐Chao Zhang

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Xu‐Chao Zhang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xu‐Chao Zhang. The network helps show where Xu‐Chao Zhang may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Xu‐Chao Zhang, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Xu‐Chao Zhang Line = papers co-authored together Xu‐Chao Zhang links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Enhancement of the cycling stability of the nickel-rich cathode material LiNi _0.9 Co _0.01 Mn _0.09 O ₂ via Nb ⁵⁺ doping Physical Chemistry Chemical Physics ·Jiatai Wang,Chao Fan,Yuanyuan Li,Yan Tan,Xu‐Chao Zhang,Jiting Li,Hongyun Liu,Xiaohong Ma,Changjuan Deng,Jian Li	2025	1
2	High specific capacity O3-NaNi₁/₃Fe₁/₃Mn₁/₃O₂ cathode material for sodium-ion batteries Solid State Ionics ·Jiatai Wang,Hongyun Liu,Yan Tan,Chao Fan,Yuanyuan Li,Jiting Li,Xu‐Chao Zhang,Y.H. Rong,Jian Li	2025	1
3	Distinct Role of TP53 Co-mutations in Different EGFR Subtypes Mediating the Response to EGFR Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer Clinical Lung Cancer ·Lihong Wei,Yi Lao,Tongze Fu,Zhongpeng Xie,Yanxia Wang,Tiantian Yang,Leilei Huang,Jiahua Liu,Man Shu,Tian Tian,Shuhua Li,Qiong He,Jianwen Zhou,Xu‐Chao Zhang,Huipin Wang,Juan Du,Xinwei Wang,Zheng Yang,Lihong Bai,Zunfu Ke	2025	0
4	The role of institutional quality in the nexus between green financing and sustainable developmentbreakdown → Research in International Business and Finance ·Xialing Sun,Zheng Meng,Xu‐Chao Zhang,Jiaxi Wu	2024	41
5	Hovering efficiency optimization of ducted propeller with large blade tip clearance based on grooved duct configuration Aerospace Science and Technology ·Yu Hu,Xu‐Chao Zhang,Guoqiang Wang,Xue Peng Zhang,Han Zhen Li	2024	25
6	Redox ^high phenotype mediated by KEAP1/STK11/SMARCA4/NRF2 mutations diminishes tissue-resident memory CD8+ T cells and attenuates the efficacy of immunotherapy in lung adenocarcinoma OncoImmunology ·Xue‐Wu Wei,Chang Lu,Yichen Zhang,Xue Fan,Chong‐Rui Xu,Zhihong Chen,Fen Wang,Xiaorong Yang,Jia‐Yi Deng,Mingyi Yang,Qing Gou,Shi‐Qi Mei,Wei‐Chi Luo,Ri-Wei Zhong,Wen‐Zhao Zhong,Jin‐Ji Yang,Xu‐Chao Zhang,Hai-Yan Tu,Yi‐Long Wu,Qing Zhou	2024	11
7	Protective role of curcumin in Singapore grouper iridovirus-induced liver injury in orange-spotted grouper (Epinephelus coioides) Aquaculture ·Yuexuan Wang,Suifeng Xu,Yewen Wang,Xu‐Chao Zhang,Jiatao Chen,Qiwei Qin,Shina Wei	2023	4
8	PD-L1 expression guidance on sintilimab versus pembrolizumab with or without platinum-doublet chemotherapy in untreated patients with advanced non-small cell lung cancer (CTONG1901): A phase 2, randomized, controlled trial Science Bulletin ·Si‐Yang Maggie Liu,Jie Huang,Jia‐Yi Deng,Chong‐Rui Xu,Hong‐Hong Yan,Mingyi Yang,Yang-Si Li,(unknown),E‐E Ke,Ming-Ying Zheng,Zhen Wang,Jiaxin Lin,Bin Gan,Xu‐Chao Zhang,Hua‐Jun Chen,Bin-Chao Wang,Hai‐Yan Tu,Jin‐Ji Yang,Wen‐Zhao Zhong,(unknown),(unknown),Qing Zhou,Yi‐Long Wu	2023	18
9	Intratumoral genetic and immune microenvironmental heterogeneity in T4N0M0 (diameter ≥ 7 cm) non‐small cell lung cancers Thoracic Cancer ·Jia‐Tao Zhang,Song Dong,Li−Yan Ji,Jiaying Zhou,Zhi− Hong Chen,Jian Su,Qing−Ge Zhu,Meng−Min Wang,E‐E Ke,Hao Sun,X. Li,Jin−Ji Yang,Qing Zhou,Xu‐Chao Zhang,Xuan Gao,Xue−Ning Yang,Xuefeng Xia,Xin Yi,Wen‐Zhao Zhong,Yi‐Long Wu	2022	2
10	Clinical outcomes of EGFR+/METamp+ vs. EGFR+/METamp‐ untreated patients with advanced non‐small cell lung cancer Thoracic Cancer ·Kai‐Cheng Peng,Junwei Su,Zhi Xie,Hanmin Wang,Mei‐Mei Fang,Wenfeng Li,Yuqing Chen,Xuhui Guan,Jian Su,Hong‐Hong Yan,Xu‐Chao Zhang,Hai‐Yan Tu,Qing Zhou,Hua‐Jun Chen,Yi‐Long Wu,Jin‐Ji Yang	2022	11
11	Clinical outcomes of non–small cell lung cancer patients with leptomeningeal metastases after immune checkpoint inhibitor treatments European Journal of Cancer ·Mei-Mei Zheng,Hai‐Yan Tu,Jin‐Ji Yang,Xu‐Chao Zhang,Qing Zhou,Chong‐Rui Xu,Ben‐Yuan Jiang,Xue‐Ning Yang,Xiaorong Yang,Jia‐Yi Deng,Mingyi Yang,Bing-Fei Xu,Xiu‐Mei Chen,Yang-Si Li,Yi‐Long Wu	2021	19
12	High SHP2 expression determines the efficacy of PD‐1/PD‐L1 inhibitors in advanced KRAS mutant non‐small cell lung cancer Thoracic Cancer ·Hui‐Bo Feng,Yu Chen,Zhi Xie,Jie Jiang,Yumin Zhong,Wei‐Bang Guo,Wenqing Yan,Zhiyi Lv,Danxia Lu,Hong‐Ling Liang,Fangping Xu,Jin‐Ji Yang,Xue‐Ning Yang,Qing Zhou,Dong‐Kun Zhang,Zhou Zhang,Shaokun Chuai,Henghui Zhang,Yi‐Long Wu,Xu‐Chao Zhang	2021	9
13	Correlation of plasma exosomal microRNAs with the efficacy of immunotherapy in EGFR/ALK wild-type advanced non-small cell lung cancer Journal for ImmunoTherapy of Cancer ·Xiaoxiao Peng,Ruoying Yu,Xue Wu,Shuyu Wu,Can Pi,Zhihong Chen,Xu‐Chao Zhang,Cun-Yi Gao,Yang Shao,Li Liu,Yi‐Long Wu,Qing Zhou	2020	146
14	Mutational landscape and characteristics of ERBB2 in non‐small cell lung cancer Thoracic Cancer ·Xue‐Wu Wei,Xin Gao,Xu‐Chao Zhang,Jin‐Ji Yang,Zhihong Chen,Yi‐Long Wu,Qing Zhou	2020	35
15	Low frequency of mutation of epidermal growth factor receptor (EGFR) and arrangement of anaplastic lymphoma kinase (ALK) in primary pulmonary lymphoepithelioma‐like carcinoma Thoracic Cancer ·Kai Yin,Hui‐Bo Feng,Lin‐Lin Li,Yu Chen,Zhi Xie,Zhiyi Lv,Wei‐Bang Guo,Danxia Lu,Xue‐Ning Yang,Wenqing Yan,Yi‐Long Wu,Xu‐Chao Zhang	2019	12
16	Heterogeneous responses and resistant mechanisms to crizotinib in ALK‐positive advanced non‐small cell lung cancer Thoracic Cancer ·Jin‐Hyoung Kang,Hua‐Jun Chen,Xu‐Chao Zhang,Jian Su,Qing Zhou,Hai‐Yan Tu,Zhen Wang,Binchao Wang,Wen‐Zhao Zhong,Xue‐Ning Yang,Zhihong Chen,Yan Ding,Xue Wu,Mei Wang,Jiangang Fu,Zhenfan Yang,Xian Zhang,Yang Shao,Yi‐Long Wu,Jin‐Ji Yang	2018	17
17	P2.03b-043 Peripheral Blood CD45RA+ CCR7+ Naive T Cells Were Correlated with Prognosis in Non-Small Cell Lung Cancer Patients Journal of Thoracic Oncology ·Shu‐Mei Huang,Si-Pei Wu,Ri-Qiang Liao,Zhong‐Yi Dong,Hai‐Yan Tu,Zhi Xie,Jian Su,Jin‐Ji Yang,Xu‐Chao Zhang,Yi‐Long Wu	2017	1
18	Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinomabreakdown → Clinical Cancer Research ·Zhong‐Yi Dong,Wen‐Zhao Zhong,Xu‐Chao Zhang,Jian Su,Zhi Xie,Si‐Yang Maggie Liu,Hai‐Yan Tu,Hua‐Jun Chen,Yue‐Li Sun,Qing Zhou,Jin‐Ji Yang,Xue‐Ning Yang,Jiaxin Lin,Hong‐Hong Yan,Hao-Ran Zhai,Li‐Xu Yan,Ri-Qiang Liao,Si-Pei Wu,Yi‐Long Wu	2016	741
19	Lung Cancers with Concomitant EGFR Mutations and ALK Rearrangements: Diverse Responses to EGFR-TKI and Crizotinib in Relation to Diverse Receptors Phosphorylation Clinical Cancer Research ·Jin-Ji Yang,Xu‐Chao Zhang,Jian Su,Chong‐Rui Xu,Qing Zhou,Hong-Xia Tian,Zhi Xie,Hua-Jun Chen,Yi-Sheng Huang,Ben‐Yuan Jiang,Zhen Wang,Bin-Chao Wang,Xue-Ning Yang,Wen‐Zhao Zhong,Qiang Nie,Ri-Qiang Liao,Tony Mok,Yi‐Long Wu	2014	135
20	[Consensus on dignosis for ALK positive non-small cell lung cancer in China, the 2013 version]. PubMed ·Xu‐Chao Zhang,Shun Lu,Li Zhang,Changli Wang,Ying Cheng,Gan‐di Li,Tony Mok,Cheng Zhi Huang,Xiaoqing Liu,Jie Wang,Mengzhao Wang,Yiping Zhang,Jianying Zhou,Xiaoyan Zhou,Dongmei Lin,Jin‐Ji Yang,Hui Li,Haiquan Chen,Wen‐Zhao Zhong,Yi‐Long Wu	2013	22

About Xu‐Chao Zhang

Xu‐Chao Zhang is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research, having authored 162 papers that have together received 5.2k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (121 papers), Lung Cancer Research Studies (36 papers), Cancer Genomics and Diagnostics (33 papers), Colorectal Cancer Treatments and Studies (30 papers), Lung Cancer Diagnosis and Treatment (28 papers), Cancer Immunotherapy and Biomarkers (21 papers), PI3K/AKT/mTOR signaling in cancer (12 papers) and Cancer therapeutics and mechanisms (9 papers). The work is most often cited by research in Oncology (3.3k citations), Pulmonary and Respiratory Medicine (3.7k citations) and Cancer Research (1.4k citations). Xu‐Chao Zhang has collaborated with scholars based in China, United States and Hong Kong. Frequent co-authors include Yi‐Long Wu, Jin‐Ji Yang, Qing Zhou, Jian Su, Wen‐Zhao Zhong, Hong‐Hong Yan, Zhi Xie, Hai‐Yan Tu, Xue‐Ning Yang and Zhihong Chen. Their work appears in journals such as Nature Communications, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact